IPCA Laboratories Ltd (IPCALAB) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 45531.03 Cr. Figures below are as reported and are shown with their source and date.
Ipca Laboratories Ltd. engages in the manufacture, research, and development of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,167 full-time employees. The firm is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. The company offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The firm offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The firm has 18 manufacturing units in India manufacturing API’s and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd and Tonira Exports Limited.
Source: finedge · as of 2026-09-29
Last close (₹): 1,903.5
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 9,646.33 | 1,141.12 | 44.98 |
| Mar 2025 | 8,939.59 | 737.68 | 29.08 |
| Mar 2024 | 7,705.04 | 547.35 | 21.57 |
| Mar 2023 | 6,244.32 | 471.32 | 18.58 |
| Mar 2022 | 5,829.79 | 884.08 | 34.85 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Figures computed 2026-10-23.